Tag: YS Biopharma
China’s YishengBio eyes US capital markets via SPAC route
Yisheng Biopharma has abandoned its Hong Kong IPO and turned instead to the Nasdaq via the SPAC route in a deal that is expected to be sealed by the first quarter of 2023
Yisheng Biopharma has abandoned its Hong Kong IPO and turned instead to the Nasdaq via the SPAC route in a deal that is expected to be sealed by the first quarter of 2023
